ACRS vs GLDG Comparison

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; Crucero project, located in Peru; Sao Jorge, Batistao, located in Brazil; Yellowknife Gold Project, located in the Northwest Territories, Canada; and various other projects such as Cachoeira, Yarumalito, Whistler, Surubim, Montes Aureos and Trinta, Rea across different locations. The company has two operating segments, with U.S. GoldMining being one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.